Abstract
B-cell lymphomas constitute the most frequent malignant neoplasm of the ocular adnexal, often presenting with localized disease. Five patients with primary localized CD20 positive B cell non Hodgkin ocular adnexal lymphomas received intralesional rituximab at the dose of 5mg once a week for one month, followed by 10mg weekly in case of incomplete response. Four of five patients obtained regression of symptoms and 2 of them showed complete response. No patients experienced side effects besides pain on the site of the injection. Local treatment with Rituximab for OAL is a safe and useful first-line therapeutic option.
Copyright © 2011 Elsevier Ltd. All rights reserved.
MeSH terms
-
Aged
-
Antibodies, Monoclonal, Murine-Derived / administration & dosage*
-
Antibodies, Monoclonal, Murine-Derived / adverse effects
-
Antigens, CD20 / immunology
-
Antigens, CD20 / metabolism
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Female
-
Humans
-
Injections, Intralesional
-
Lymphoma
-
Lymphoma, Non-Hodgkin / diagnostic imaging
-
Lymphoma, Non-Hodgkin / drug therapy
-
Magnetic Resonance Imaging
-
Male
-
Middle Aged
-
Neoadjuvant Therapy
-
Orbital Neoplasms / diagnostic imaging
-
Orbital Neoplasms / drug therapy
-
Pilot Projects
-
Radiography
-
Remission Induction
-
Rituximab
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal, Murine-Derived
-
Antigens, CD20
-
Antineoplastic Agents
-
Rituximab